{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:16:43Z","timestamp":1783516603929,"version":"3.55.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"publisher","award":["GARO_BIRD23_01"],"award-info":[{"award-number":["GARO_BIRD23_01"]}],"id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["CN00000041"],"award-info":[{"award-number":["CN00000041"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2022\/47\/D\/NZ7\/03212"],"award-info":[{"award-number":["2022\/47\/D\/NZ7\/03212"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005632","name":"Narodowe Centrum Bada\u0144 i Rozwoju","doi-asserted-by":"publisher","award":["0258\/L-14\/2023"],"award-info":[{"award-number":["0258\/L-14\/2023"]}],"id":[{"id":"10.13039\/501100005632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s13346-025-01997-4","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:11:37Z","timestamp":1762171897000},"page":"2678-2696","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dynamic 3D microfluidic platform for exploring combined targeted therapy, chemotherapy, and virotherapy delivery in ovarian cancer"],"prefix":"10.1007","volume":"16","author":[{"given":"Lukasz","family":"Kuryk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mathlouthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Casagrande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Pesce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tognetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Malfanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Masny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Caliceti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5001-7826","authenticated-orcid":false,"given":"Mariangela","family":"Garofalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"11","key":"1997_CR1","doi-asserted-by":"publisher","first-page":"868","DOI":"10.5306\/WJCO.V11.I11.868","volume":"11","author":"L Feeney","year":"2020","unstructured":"Feeney L, Harley IJ, McCluggage WG, Mullan PB, Beirne JP. Liquid biopsy in ovarian cancer: catching the silent killer before it strikes. World J Clin Oncol. 2020;11(11):868\u201389. https:\/\/doi.org\/10.5306\/WJCO.V11.I11.868.","journal-title":"World J Clin Oncol"},{"key":"1997_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.5114\/PM.2023.128661","volume":"22","author":"AT Ali","year":"2023","unstructured":"Ali AT, Al-Ani O, Al-Ani F. Epidemiology and risk factors for ovarian cancer. Menopausal Review. 2023;22:93\u2013104. https:\/\/doi.org\/10.5114\/PM.2023.128661.","journal-title":"Menopausal Review"},{"key":"1997_CR3","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/IJC.34002","volume":"151","author":"CJ Cabasag","year":"2022","unstructured":"Cabasag CJ, Fagan PJ, Ferlay J, Vignat J, Laversanne M, Liu L, van der Aa MA, Bray F, Soerjomataram I. Ovarian cancer today and tomorrow: a global assessment by world region and Human Development Index using GLOBOCAN 2020. Int J Cancer. 2022;151:1535\u201341. https:\/\/doi.org\/10.1002\/IJC.34002.","journal-title":"Int J Cancer"},{"key":"1997_CR4","doi-asserted-by":"publisher","unstructured":"Zhu JW, Charkhchi P, Akbari MR. Potential clinical utility of liquid biopsies in ovarian cancer. Mol Cancer. 2022;21(1):1\u201324. https:\/\/doi.org\/10.1186\/S12943-022-01588-8.","DOI":"10.1186\/S12943-022-01588-8"},{"issue":"11","key":"1997_CR5","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/S11912-024-01587-6","volume":"26","author":"IV Rodriguez","year":"2024","unstructured":"Rodriguez IV, Ghezelayagh T, Pennington KP, Norquist BM. Prevention of ovarian cancer: where are we now and where are we going? Curr Oncol Rep. 2024;26(11):1355\u201366. https:\/\/doi.org\/10.1007\/S11912-024-01587-6.","journal-title":"Curr Oncol Rep"},{"key":"1997_CR6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/PAT.0B013E328348A6E7","volume":"43","author":"WG McCluggage","year":"2011","unstructured":"McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43:420\u201332. https:\/\/doi.org\/10.1097\/PAT.0B013E328348A6E7.","journal-title":"Pathology"},{"key":"1997_CR7","doi-asserted-by":"publisher","unstructured":"Ozols RF. Challenges for chemotherapy in ovarian cancer. Ann Oncol. 2006;17 (Suppl 5). https:\/\/doi.org\/10.1093\/ANNONC\/MDJ978.","DOI":"10.1093\/ANNONC\/MDJ978"},{"key":"1997_CR8","doi-asserted-by":"publisher","unstructured":"Freyer G, Floquet A, Tredan O, Carrot A, Langlois-Jacques C, Lopez J, Selle F, Abdeddaim C, Leary A, Dubot-Poitelon C, Fabbro M, Gladieff L, Lamuraglia M. Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nat Commun. 2024;15(1):1\u201311. https:\/\/doi.org\/10.1038\/s41467-024-45974-w.","DOI":"10.1038\/s41467-024-45974-w"},{"issue":"12","key":"1997_CR9","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41571-023-00819-1","volume":"20","author":"AC Veneziani","year":"2023","unstructured":"Veneziani AC, Gonzalez-Ochoa E, Alqaisi H, Madariaga A, Bhat G, Rouzbahman M, Sneha S, Oza AM. Heterogeneity and treatment landscape of ovarian carcinoma. Nat Rev Clin Oncol. 2023;20(12):820\u201342. https:\/\/doi.org\/10.1038\/s41571-023-00819-1.","journal-title":"Nat Rev Clin Oncol"},{"key":"1997_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/S10534-023-00547-0\/FIGURES\/5","volume":"37","author":"E Baglini","year":"2024","unstructured":"Baglini E, Chiaverini L, Tolbatov I, Taliani S, Da Settimo F, La Mendola D, Barresi E, Marzo T. Tyrosine kinase inhibitors (TKIs) for ovarian cancer treatment: from organic to inorganic chemotherapeutics towards selectivity\u2014a perspective overview. Biometals. 2024;37:275\u201388. https:\/\/doi.org\/10.1007\/S10534-023-00547-0\/FIGURES\/5.","journal-title":"Biometals"},{"key":"1997_CR11","doi-asserted-by":"publisher","unstructured":"Wang L, Wang X, Zhu X, Zhong L, Jiang Q, Wang Y, Tang Q, Li Q, Zhang C, Wang H, Zou D. Drug resistance in ovarian cancer: from mechanism to clinical trial. Mol Cancer. 2024;23(1):1\u201326. https:\/\/doi.org\/10.1186\/S12943-024-01967-3.","DOI":"10.1186\/S12943-024-01967-3"},{"key":"1997_CR12","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/J.GENDIS.2020.11.017","volume":"9","author":"C Guo","year":"2022","unstructured":"Guo C, Song C, Zhang J, Gao Y, Qi Y, Zhao Z, Yuan C. Revisiting chemoresistance in ovarian cancer: mechanism, biomarkers, and precision medicine. Genes Dis. 2022;9:668\u201381. https:\/\/doi.org\/10.1016\/J.GENDIS.2020.11.017.","journal-title":"Genes Dis"},{"key":"1997_CR13","doi-asserted-by":"publisher","first-page":"1259314","DOI":"10.3389\/FONC.2023.1259314\/BIBTEX","volume":"13","author":"M Garofalo","year":"2023","unstructured":"Garofalo M, Wieczorek M, Anders I, Staniszewska M, Lazniewski M, Prygiel M, Zasada AA, Szczepi\u0144ska T, Plewczynski D, Salmaso S, Caliceti P, Cerullo V, Alemany R, Rinner B, Pancer K, Kuryk L. Novel combinatorial therapy of oncolytic adenovirus AdV5\/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model. Front Oncol. 2023;13:1259314. https:\/\/doi.org\/10.3389\/FONC.2023.1259314\/BIBTEX.","journal-title":"Front Oncol"},{"key":"1997_CR14","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/IJC.30228","volume":"139","author":"L Kuryk","year":"2016","unstructured":"Kuryk L, Haavisto E, Garofalo M, Capasso C, Hirvinen M, Pesonen S, Ranki T, Vassilev L, Cerullo V. Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5\/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model. Int J Cancer. 2016;139:1883\u201393. https:\/\/doi.org\/10.1002\/IJC.30228.","journal-title":"Int J Cancer"},{"key":"1997_CR15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3390\/PHARMACEUTICS13040547\/S1","volume":"13","author":"M Garofalo","year":"2021","unstructured":"Garofalo M, Bertinato L, Staniszewska M, Wieczorek M, Salmaso S, Schrom S, Rinner B, Pancer KW, Kuryk L. Combination therapy of novel oncolytic adenovirus with anti-pd1 resulted in enhanced anti-cancer effect in syngeneic immunocompetent melanoma mouse model. Pharmaceutics. 2021;13:547. https:\/\/doi.org\/10.3390\/PHARMACEUTICS13040547\/S1.","journal-title":"Pharmaceutics"},{"key":"1997_CR16","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.omto.2023.01.002","volume":"28","author":"L Kuryk","year":"2023","unstructured":"Kuryk L, M\u00f8ller ASW. Next generation oncolytic viruses expressing PADI1 and TIMP2 exhibit anti-tumor activity against melanoma in nude and humanized mouse models. Mol Ther Oncolytics. 2023;28:158\u201370. https:\/\/doi.org\/10.1016\/j.omto.2023.01.002.","journal-title":"Mol Ther Oncolytics"},{"key":"1997_CR17","doi-asserted-by":"publisher","unstructured":"Kuryk L, M\u00f8ller ASW, Vuolanto A, Pesonen S, Garofalo M, Cerullo V, Jaderberg M. Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks. Int J Mol Sci. 2019;20;621. https:\/\/doi.org\/10.3390\/IJMS20030621.","DOI":"10.3390\/IJMS20030621"},{"key":"1997_CR18","doi-asserted-by":"publisher","unstructured":"Kuryk L, M\u00f8ller AS, Jaderberg M. Quantification and functional evaluation of CD40L production from the adenovirus vector ONCOS-401. Cancer Gene Therapy. 2018;26(1):26\u201331. https:\/\/doi.org\/10.1038\/s41417-018-0038-x.","DOI":"10.1038\/s41417-018-0038-x"},{"key":"1997_CR19","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3390\/PHARMACEUTICS13070949\/S1","volume":"13","author":"M Garofalo","year":"2021","unstructured":"Garofalo M, Bellato F, Magliocca S, Malfanti A, Kuryk L, Rinner B, Negro S, Salmaso S, Caliceti P, Mastrotto F. Polymer coated oncolytic adenovirus to selectively target hepatocellular carcinoma cells. Pharmaceutics. 2021;13:949. https:\/\/doi.org\/10.3390\/PHARMACEUTICS13070949\/S1.","journal-title":"Pharmaceutics"},{"key":"1997_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJPB.2024.114300","volume":"199","author":"L Kuryk","year":"2024","unstructured":"Kuryk L, Mathlouthi S, Wieczorek M, Gad B, Rinner B, Malfanti A, Mastrotto F, Salmaso S, Caliceti P, Garofalo M. Priming with oncolytic adenovirus followed by anti-PD-1 and paclitaxel treatment leads to improved anti-cancer efficacy in the 3D TNBC model. Eur J Pharm Biopharm. 2024;199: 114300. https:\/\/doi.org\/10.1016\/J.EJPB.2024.114300.","journal-title":"Eur J Pharm Biopharm"},{"key":"1997_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/S10238-024-01541-7","volume":"25","author":"A Chekaoui","year":"2024","unstructured":"Chekaoui A, Garofalo M, Gad B, Staniszewska M, Chiaro J, Pancer K, Gryciuk A, Cerullo V, Salmaso S, Caliceti P, Masny A, Wieczorek M, Pesonen S, Kuryk L. Cancer vaccines: an update on recent achievements and prospects for cancer therapy. Clin Exp Med. 2024;25:24. https:\/\/doi.org\/10.1007\/S10238-024-01541-7.","journal-title":"Clin Exp Med"},{"key":"1997_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/NOAJNL\/VDAD081","volume":"5","author":"JD Bernstock","year":"2023","unstructured":"Bernstock JD, Blitz SE, Hoffman SE, Gerstl JVE, Chiocca EA, Friedman GK. Recent oncolytic virotherapy clinical trials outline a roadmap for the treatment of high-grade glioma. Neuro-Oncol Adv. 2023;5:1\u20137. https:\/\/doi.org\/10.1093\/NOAJNL\/VDAD081.","journal-title":"Neuro-Oncol Adv"},{"key":"1997_CR23","doi-asserted-by":"publisher","first-page":"953410","DOI":"10.3389\/FIMMU.2022.953410\/PDF","volume":"13","author":"CO Yun","year":"2022","unstructured":"Yun CO, Hong JW, Yoon AR. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements. Front Immunol. 2022;13:953410. https:\/\/doi.org\/10.3389\/FIMMU.2022.953410\/PDF.","journal-title":"Front Immunol"},{"key":"1997_CR24","doi-asserted-by":"publisher","unstructured":"Robinson C, Xu MM, Nair SK, Beasley GM, Rhodin KE. Oncolytic viruses in melanoma. Front Biosci - Landmark. 2022;27:63. https:\/\/doi.org\/10.31083\/J.FBL2702063\/2768-6698-27-2-063.PDF.","DOI":"10.31083\/J.FBL2702063\/2768-6698-27-2-063.PDF"},{"key":"1997_CR25","doi-asserted-by":"publisher","unstructured":"Koz\u0142owska E, Vallius T, Hynninen J, Hietanen S, F\u00e4rkkil\u00e4 A, Hautaniemi S. Virtual clinical trials identify effective combination therapies in ovarian cancer. Sci Rep. 2019:9:1 9 (2019) 1\u20139. https:\/\/doi.org\/10.1038\/s41598-019-55068-z.","DOI":"10.1038\/s41598-019-55068-z"},{"key":"1997_CR26","doi-asserted-by":"publisher","unstructured":"Hockings H, Miller RE. The role of PARP inhibitor combination therapy in ovarian cancer. Ther Adv Med Oncol. 2023;15. https:\/\/doi.org\/10.1177\/17588359231173183\/ASSET\/C0D28267-0A37-49C9-B102-43DDDB38103A\/ASSETS\/IMAGES\/LARGE\/10.1177_17588359231173183-FIG1.JPG.","DOI":"10.1177\/17588359231173183\/ASSET\/C0D28267-0A37-49C9-B102-43DDDB38103A\/ASSETS\/IMAGES\/LARGE\/10.1177_17588359231173183-FIG1.JPG"},{"key":"1997_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/celldisc.2017.42","volume":"3","author":"X Li","year":"2017","unstructured":"Li X, Ba Q, Liu Y, Yue Q, Chen P, Li J, Zhang H, Ying H, Ding Q, Song H, Liu H, Zhang R, Wang H. Dihydroartemisinin selectively inhibits PDGFR\u03b1-positive ovarian cancer growth and metastasis through inducing degradation of PDGFR\u03b1 protein. Cell Discovery. 2017;3:1\u20133. https:\/\/doi.org\/10.1038\/celldisc.2017.42.","journal-title":"Cell Discovery"},{"key":"1997_CR28","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.3892\/OL.2014.2818\/HTML","volume":"9","author":"Z He","year":"2015","unstructured":"He Z, Li B, Rankin GO, Rojanasakul Y, Chen YC. Phenolic compound, ovarian cancer, cell viability, vascular endothelial growth factor, hypoxia-inducible factor-1\u03b1. Oncol Lett. 2015;9:1444\u201350. https:\/\/doi.org\/10.3892\/OL.2014.2818\/HTML.","journal-title":"Oncol Lett"},{"key":"1997_CR29","doi-asserted-by":"publisher","first-page":"10817","DOI":"10.3390\/IJMS221910817","volume":"22","author":"YR Na","year":"2021","unstructured":"Na YR, Kim JY, Song CH, Kim M, Do YT, Vo TTL, Choi E, Ha E, Seo JH, Shin SJ. The FGFR Family Inhibitor AZD4547 Exerts an Antitumor Effect in Ovarian Cancer Cells. International Journal of Molecular Sciences. 2021;22:10817. https:\/\/doi.org\/10.3390\/IJMS221910817.","journal-title":"International Journal of Molecular Sciences"},{"key":"1997_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000493361","volume":"84","author":"F Barra","year":"2019","unstructured":"Barra F, Lagan\u00e0 AS, Ghezzi F, Casarin J, Ferrero S. Nintedanib for advanced epithelial ovarian cancer: a change of perspective? Summary of evidence from a systematic review. Gynecol Obstet Invest. 2019;84:107\u201317. https:\/\/doi.org\/10.1159\/000493361.","journal-title":"Gynecol Obstet Invest"},{"key":"1997_CR31","doi-asserted-by":"publisher","first-page":"910","DOI":"10.5114\/AOMS.2016.63743","volume":"14","author":"M Kapa\u0142czy\u0144ska","year":"2018","unstructured":"Kapa\u0142czy\u0144ska M, Kolenda T, Przyby\u0142a W, Zaj\u0105czkowska M, Teresiak A, Filas V, Ibbs M, Bli\u017aniak R, \u0141uczewski \u0141, Lamperska K. 2D and 3D cell cultures \u2013 a comparison of different types of cancer cell cultures. Arch Med Sci. 2018;14:910\u20139. https:\/\/doi.org\/10.5114\/AOMS.2016.63743.","journal-title":"Arch Med Sci"},{"key":"1997_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/FMOLB.2020.00033\/REFERENCE","volume":"7","author":"C Jensen","year":"2020","unstructured":"Jensen C, Teng Y. Is It Time to Start Transitioning From 2D to 3D Cell Culture? Front Mol Biosci. 2020;7: 513823. https:\/\/doi.org\/10.3389\/FMOLB.2020.00033\/REFERENCE.","journal-title":"Front Mol Biosci"},{"key":"1997_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7150\/NTNO.47226","volume":"5","author":"M Garofalo","year":"2021","unstructured":"Garofalo M, Villa A, Brunialti E, Crescenti D, Dell\u2019omo G, Kuryk L, Vingiani A, Mazzaferro V, Ciana P. Cancer-derived EVs show tropism for tissues at early stage of neoplastic transformation. Nanotheranostics. 2021;5:1\u20137. https:\/\/doi.org\/10.7150\/NTNO.47226.","journal-title":"Nanotheranostics"},{"key":"1997_CR34","unstructured":"Ofev | European Medicines Agency (EMA). (n.d.). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ofev. Accessed 10 Mar 2025."},{"key":"1997_CR35","unstructured":"CHMP, Apexelsin, INN-paclitaxel, (n.d.). www.ema.europa.eu\/contact . Accessed 10 Mar 2025."},{"key":"1997_CR36","unstructured":"Annex I Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s), (n.d.). https:\/\/www.ema.europa.eu\/en\/documents\/psusa\/colchicine-cmdh-scientific-conclusions-and-grounds-variation-amendments-productinformation-and-timetable-implementation-psusa00000858201807_en.pdf. Accessed 10 July 2019."},{"key":"1997_CR37","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/JMV.25677","volume":"92","author":"L Kuryk","year":"2020","unstructured":"Kuryk L, M\u00f8ller ASW. Chimeric oncolytic Ad5\/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor. J Med Virol. 2020;92:1309\u201315. https:\/\/doi.org\/10.1002\/JMV.25677.","journal-title":"J Med Virol"},{"key":"1997_CR38","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.7150\/JCA.71992","volume":"13","author":"M Garofalo","year":"2022","unstructured":"Garofalo M, Pancer KW, Wieczorek M, Staniszewska M, Salmaso S, Caliceti P, Kuryk L. From immunosuppression to immunomodulation - turning cold tumours into hot. J Cancer. 2022;13:2884\u201392. https:\/\/doi.org\/10.7150\/JCA.71992.","journal-title":"J Cancer"},{"key":"1997_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2023-007552","author":"S Ponce","year":"2023","unstructured":"Ponce S, Cedr\u00e9s S, Ricordel C, Isambert N, Viteri S, Herrera-Juarez M, Martinez-Marti A, Navarro A, Lederlin M, Serres X, Zugazagoitia J, Vetrhus S, Jaderberg M, Hansen TB, Levitsky V, Paz-Ares L. ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/JITC-2023-007552.","journal-title":"J Immunother Cancer"},{"key":"1997_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2023.1162905","volume":"14","author":"RM Visalakshan","year":"2023","unstructured":"Visalakshan RM, Lowrey MK, Sousa MGC, Helms HR, Samiea A, Schutt CE, Moreau JM, Bertassoni LE. Opportunities and challenges to engineer 3D models of tumor-adaptive immune interactions. Front Immunol. 2023;14: 1162905. https:\/\/doi.org\/10.3389\/FIMMU.2023.1162905.","journal-title":"Front Immunol"},{"key":"1997_CR41","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.3390\/CANCERS12103057","volume":"12","author":"L Kuryk","year":"2020","unstructured":"Kuryk L, Bertinato L, Staniszewska M, Pancer K, Wieczorek M, Salmaso S, Caliceti P, Garofalo M. From conventional therapies to immunotherapy: melanoma treatment in review. Cancers (Basel). 2020;12:3057. https:\/\/doi.org\/10.3390\/CANCERS12103057.","journal-title":"Cancers (Basel)"},{"key":"1997_CR42","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.7150\/THNO.58390","volume":"11","author":"YT Liu","year":"2021","unstructured":"Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11:5365. https:\/\/doi.org\/10.7150\/THNO.58390.","journal-title":"Theranostics"},{"key":"1997_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2015.1017702","volume":"4","author":"L Vassilev","year":"2015","unstructured":"Vassilev L, Ranki T, Joensuu T, J\u00e4ger E, Karbach J, Wahle C, Partanen K, Kairemo K, Alanko T, Turkki R, Linder N, Lundin J, Ristim\u00e4ki A, Kankainen M, Hemminki A, Backman C, Dienel K, von Euler M, Haavisto E, Hakonen T, Juhila J, J\u00e4derberg M, Priha P, Vuolanto A, Pesonen S. Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer. Oncoimmunology. 2015;4:1\u20135. https:\/\/doi.org\/10.1080\/2162402X.2015.1017702.","journal-title":"Oncoimmunology"},{"key":"1997_CR44","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/J.JCONREL.2024.10.057","volume":"376","author":"S Mathlouthi","year":"2024","unstructured":"Mathlouthi S, Kuryk L, Prygiel M, Lupo MG, Zasada AA, Pesce C, Ferri N, Rinner B, Salmaso S, Garofalo M. Extracellular vesicles powered cancer immunotherapy: targeted delivery of adenovirus-based cancer vaccine in humanized melanoma model. J Control Release. 2024;376:777\u201393. https:\/\/doi.org\/10.1016\/J.JCONREL.2024.10.057.","journal-title":"J Control Release"},{"key":"1997_CR45","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/J.CANLET.2014.12.027","volume":"358","author":"N Awasthi","year":"2015","unstructured":"Awasthi N, Hinz S, Brekken RA, Schwarz MA, Schwarz RE. Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. Cancer Lett. 2015;358:59\u201366. https:\/\/doi.org\/10.1016\/J.CANLET.2014.12.027.","journal-title":"Cancer Lett"},{"key":"1997_CR46","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1023\/A:1008265012435","volume":"9","author":"P Perego","year":"1998","unstructured":"Perego P, Romanelli S, Carenini N, Magnani I, Leone R, Bonetti A, Paolicchi A, Zunino F. Ovarian cancer cisplatin-resistant cell lines: Multiple changes including collateral sensitivity to Taxol. Annals of Oncolooy. 1998;9:423\u201330. https:\/\/doi.org\/10.1023\/A:1008265012435.","journal-title":"Annals of Oncolooy"},{"key":"1997_CR47","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1158\/1078-0432.CCR-14-0713\/86366\/AM\/PRECLINICAL-ACTIVITY-OF-THE-LIPOSOMAL-CISPLATIN","volume":"20","author":"N Casagrande","year":"2014","unstructured":"Casagrande N, Celegato M, Borghese C, Mongiat M, Colombatti A, Aldinucci D. Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer. Clin Cancer Res. 2014;20:5496\u2013506. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0713\/86366\/AM\/PRECLINICAL-ACTIVITY-OF-THE-LIPOSOMAL-CISPLATIN.","journal-title":"Clin Cancer Res"},{"key":"1997_CR48","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/0959-8049(95)00056-O","volume":"31","author":"A Riccardi","year":"1995","unstructured":"Riccardi A, Servidei T, Tornesello A, Puggioni P, Mastrangelo S, Rumi C, Riccardi R. Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines. Eur J Cancer. 1995;31:494\u20139. https:\/\/doi.org\/10.1016\/0959-8049(95)00056-O.","journal-title":"Eur J Cancer"},{"issue":"7","key":"1997_CR49","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/1097-0142(19941001)74:7","volume":"74","author":"LM Adler","year":"1994","unstructured":"Adler LM, Herzog TJ, Williams S, Rader JS, Mutch DG. Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines. Cancer. 1994;74(7):1891\u20138. https:\/\/doi.org\/10.1002\/1097-0142(19941001)74:7.","journal-title":"Cancer"},{"key":"1997_CR50","doi-asserted-by":"publisher","unstructured":"Liu B, Zhou H, Tan L, Siu KTH, Guan XY. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther. 2024;9(1):1\u201344. https:\/\/doi.org\/10.1038\/s41392-024-01856-7.","DOI":"10.1038\/s41392-024-01856-7"},{"key":"1997_CR51","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.7150\/THNO.40298","volume":"10","author":"J Yang","year":"2020","unstructured":"Yang J, Shi Z, Liu R, Wu Y, Zhang X. Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment via nanotechnology. Theranostics. 2020;10:3223. https:\/\/doi.org\/10.7150\/THNO.40298.","journal-title":"Theranostics"},{"key":"1997_CR52","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/ONCOTARGET.16723","volume":"8","author":"RB Mokhtari","year":"2017","unstructured":"Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H. Combination therapy in combating cancer. Oncotarget. 2017;8:38022. https:\/\/doi.org\/10.18632\/ONCOTARGET.16723.","journal-title":"Oncotarget"},{"issue":"1","key":"1997_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS19010181","volume":"19","author":"J Hoarau-V\u00e9chot","year":"2018","unstructured":"Hoarau-V\u00e9chot J, Rafii A, Touboul C, Pasquier J. Halfway between 2D and animal models: are 3D cultures the ideal tool to study cancer-microenvironment interactions? Int J Mol Sci. 2018;19(1): 181. https:\/\/doi.org\/10.3390\/IJMS19010181.","journal-title":"Int J Mol Sci"},{"key":"1997_CR54","doi-asserted-by":"publisher","unstructured":"Abbas ZN, Al-Saffar AZ, Jasim SM, Sulaiman GM. Comparative analysis between 2D and 3D colorectal cancer culture models for insights into cellular morphological and transcriptomic variations. Sci Rep. 2023;13(1):1\u201316. https:\/\/doi.org\/10.1038\/s41598-023-45144-w.","DOI":"10.1038\/s41598-023-45144-w"},{"key":"1997_CR55","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/S41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov H, Orhan A, Christensen JP, G\u00f6genur I. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124:359\u201367. https:\/\/doi.org\/10.1038\/S41416-020-01048-4.","journal-title":"Br J Cancer"},{"key":"1997_CR56","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231173183","author":"H Hockings","year":"2023","unstructured":"Hockings H, Miller RE. The role of PARP inhibitor combination therapy in ovarian cancer. Ther Adv Med Oncol. 2023. https:\/\/doi.org\/10.1177\/17588359231173183.","journal-title":"Ther Adv Med Oncol"},{"key":"1997_CR57","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12943-023-01911-x","volume":"23","author":"Y Wang","year":"2024","unstructured":"Wang Y, Suarez R, Kastrunes G, Santos N, De Campos P, Abbas R, Pivetta RS, Murugan N, Chalbatani GM, D\u2019Andrea V, Marasco WA. REVIEW Open Access Evolution of cell therapy for renal cell carcinoma. Mol Cancer. 2024;23:8. https:\/\/doi.org\/10.1186\/s12943-023-01911-x.","journal-title":"Mol Cancer"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01997-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-01997-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01997-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T12:32:40Z","timestamp":1783513960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-01997-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1997"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-01997-4","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We, the authors, give our full consent for the publication of our manuscript titled: \u201cDynamic 3D Microfluidic Platform for Exploring Combined Targeted Therapy, Chemotherapy, and Virotherapy Delivery in Ovarian Cancer\u201d in Drug Delivery and Translational Research, confirming that we have contributed to the work, reviewed the final version, and agreed to its submission. We affirm that the manuscript is original and complies with ethical and copyright requirements\n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Author L.K. is an employee and\/or shareholder in Valo Therapeutics. The other authors declare that the work was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}